Corticosteroid-induced glaucoma: A review of the literature

Eye

Volumn 20, Issue 4, 2006, Pages 407-416

  Kersey, J P ^a   Broadway, D C ^a  

^a NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Corticosteroid; Glaucoma; Intraocular pressure; Myocilin; Secondary; Steroid induced

Indexed keywords

ACETAZOLAMIDE; ANTIGLAUCOMA AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; BRINZOLAMIDE; CORTICOSTEROID; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DORZOLAMIDE; FLUOCINOLONE ACETONIDE; FLUOROMETHOLONE; HYDROCORTISONE; LATANOPROST; MEDRYSONE; METHOTREXATE; MIFEPRISTONE; MIOTIC AGENT; MYOCILIN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; RIMEXOLONE; TETRAHYDROCORTISOL; TETRAHYDROTRIAMCINOLONE; TRIAMCINOLONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARGON LASER; CORNEA EDEMA; CYTOLOGY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; FILTERING OPERATION; GENE ISOLATION; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; MEDICAL DECISION MAKING; MEDICAL GENETICS; MEDICAL LITERATURE; MOLECULAR BIOLOGY; NONHUMAN; RETINA MACULA EDEMA; REVIEW; RISK FACTOR; SUBRETINAL FLUID; TRABECULOPLASTY; TREATMENT PLANNING; UVEITIS;

EID: 33645760204     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6701895     Document Type: Review

References (80)

1. McLean JM. Use of ACTH and cortisone. Trans Am Ophthalmol Soc 1950; 48: 293-296.
2. Francois J. Cortisone et tension oculaire. Ann D'Oculist 1954; 187: 805.
3. Smith CL. Corticosteroid glaucoma: A summary and review of the literature. Am J Med Sci 1966; 252: 239-244.
4. Bayer JM, Neuner NP. Cushing-syndrom und erhohter augeninnen druck. Deutsch Med Wochenschr 1967; 92: 1971.
5. Haas JS, Nootens RH. Glaucoma secondary to benign adrenal adenoma. Am J Ophthalmol 1974; 78: 497.
6. Becker B, Mills DW. Corticosteroids and intraocular pressure. Arch Ophthalmol 1963; 70: 500-507.
7. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: I. The effect of dexamethasone in the normal eye. Arch Ophthalmol 1963; 70: 482-491.
8. Armaly MF. Effect of corticosteroids on intraocular pressure and fluid dynamics: II. The effect of dexamethasone on the glaucomatous eye. Arch Ophthalmol 1963; 70: 492-499.
9. Gaston H, Absolon MJ, Thurtle OA, Sattar MA. Steroid responsiveness in connective tissue diseases. Br J Ophthalmol 1983; 67: 487-490.
10. Becker B. Diabetes mellitus and primary open-angle glaucoma. Am J Ophthalmol 1971; 71: 1-16.
11. Becker B. Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965; 26: 198-205.
12. Becker B, Hahn KA. Topical corticosteroids and heredity in primary open-angle glaucoma. Am J Ophthalmol 1964; 54: 543-551.
13. Davies TG. Tonographic survey of the close relatives of patients with chronic simple glaucoma. Br J Ophthalmol 1968; 52: 32-39.
14. Podos SM, Becker B, Morton WR. High myopia and primary open-angle glaucoma. Am J Ophthalmol 1966; 62: 1038-1043.
15. Spaeth GL. Traumatic hyphaema, angle recession, dexamethasone hypertension, and glaucoma. Arch Ophthalmol 1967; 78: 714-721.
16. Miller D, Peczon JD, Whitworth CG. Corticosteroids and functions in the anterior segment of the eye. Am J Ophthalmol 1965; 59: 31-34.
17. Spaeth GL. The effect of autonomic agents on the pupil and the intraocular pressure of eyes treated with dexamethasone. Br J Ophthalmol 1980; 64: 426-429.
18. Francois J. Corticosteroid glaucoma. Ann Ophthalmol 1977; 9: 1075-1080.
19. Bernstein HN, Mills DW, Becker B. Steroid-induced elevation of intraocular pressure. Arch Ophthalmol 1963; 70: 15-18.
20. Cubey RB. Glaucoma following the application of corticosteroid to the skin of the eyelids. Br J Dermatol 1976; 95: 207-208.
21. Garbe E, Lorier J, Boivin JF, Siussa S. Inhaled and nasal glucocorticoids and the risk of ocular hypertension or open-angle glaucoma. JAMA 1997; 277: 722-727.
22. Kalina RE. Increased intraocular pressure following subconjunctival corticosteroid administration. Arch Ophthalmol 1969; 81: 78-90.
23. Chen SD, Lochhead J, Patel CK, Frith P. Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion. Br J Ophthamol 2004; 88(1): 154-155.
24. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamconolone acetonide for choroidal neovascularization. Ophthamology 2003; 110: 1517-1525.
25. Gillies MC, Simpson JM, Billson FA, Luo W, Penfold P, Chua W et al. Safety of an intravitreal injection of triamcinolone: Results from a randomized clinical trial. Arch Ophthalmol 2004; 122: 336-340.
26. Kaushik S, Gupta V, Gupta A, Dogra MR, Singh R. Intractable glaucoma following intravitreal triamcinolone in central retinal vein occlusion. Am J Ophthalmol 2004; 137: 758-760.
27. Cantrill HL, Palmberg, Zink HA, Waltman SR, Podos SM, Becker B. Comparison of in vitro potency of corticosteroids with ability to raise intraocular pressure. Am J Ophthalmol 1975; 79: 1012-1017.
28. Herschler J. Increased intraocular pressure induced by repository corticosteroids. Am J Ophthalmol 1976; 82: 90-93.
29. Weinreb RN, Polansky JR, Kramer SG, Baxter JD. Acute effects of dexamethasone on intraocular pressure in glaucoma. Invest Ophthalmol Vis Sci 1985; 26(2): 170-175.
30. Bernstein HN, Schwartz B. Effects of long term systemic steroids on ocular pressure and Tonographic values. Arch Ophthalmol 1962; 68: 742.
31. Renfro L, Snow JS. Ocular effects of topical and systemic steroids. Dermatol Clin 1992; 10: 505-510.
32. Wordinger RJ, Clark AF. Effects of glucocorticoids on the trabecular meshwork: Towards a better understanding of glaucoma. Prog Retina Eye Res 1999; 18: 629-667.
33. McCarty GR, Schwartz B. Increased concentration of glucocorticoid receptors in rabbit iris-ciliary body compared to rabbit liver. Invest Ophthalmol Vis Sci 1982; 23: 525-528.
34. Tchernitchiv A, Wenk EJ, Hernandez MR, Weinstein BI, Dunn MW, Gordon GG et al. Glucocorticoid localization by radioautography in the rabbit eye following systemic administration of 3H-dexamethasone. Invest Ophthalmol Vis Sci 1980; 19: 1231-1236.
35. Weinreb RN, Mitchell MD, Polansky JR. Prostaglandin production by human trabecular meshwork cells: In vitro inhibition by dexamethasone. Invest Ophthalmol Vis Sci 1983; 24: 1541-1545.
36. Tripathi BJ, Tripathi RC, Swift HH. Hydrocortisone-induced DNA endoreplication in human trabecular cell in vitro. Exp Eye Res 1989; 49: 259-270.
37. Wilson K, McCartney MD, Miggans ST, Clark AF. Dexamethasone induced ultrastructural changes in cultured human trabecular meshwork cells. Curr Eye Res 1993; 12: 783-793.
38. Yue BYJT. The extracellular matrix and its modulation in the trabecular meshwork. Surv Ophthalmol 1996; 40: 379-390.
39. Snyder RW, Stamer WD, Kramer TR, Seftor REB. Corticosteroid treatment and trabecular meshwork proteases in cell and organ culture supernatants. Exp Eye Res 1993; 57: 461-468.
40. Spaeth GL, Rodgriguez MM, Weinreb S. Steroid-induced glaucoma: A. Persistent elevation of intraocular pressure. B. Histopathological aspects. Trans Am Ophthalmol Soc 1977; 75: 353-381.
41. Ticho U, Lahav M, Berkowitz S, Yoffe P. Ocular changes in rabbits with corticosteroid-induced ocular hypertension. Br J Ophthalmol 1979; 63: 646-650.
42. Shirato S, Bloom E, Polansky J, Alvarado J, Stilwell L. Phagocytic properties of confluent human trabecular meshwork cells. Invest Ophthalmol Vis Sci 1988; 29: S125.
43. Bill A. Editorial: The drainage of aqueous humor. Invest Ophthalmol 1975; 14: 1-3.
44. Clark AF, Wilson K, McCartney MD, Miggans ST, Kunkle M, Howe W. Glucocorticocoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Invest Ophthamol Vis Sci 1994; 35: 281-294.
45. Clark AF, Wilson K, de Kater AW, Allingham R, McCartney MD. Dexamethasone-induced ocular hypertension in perfusion-cultured human eyes. Invest Ophthalmol Vis Sci 1995; 36: 478-489.
46. Johnson DH, Bradley JM, Acott TS. The effect of dexamethasone on glycosaminoglycans of human trabecular meshwork in perfusion organ culture. Invest Ophthalmol Vis Sci 1990; 31: 2568-2571.
47. Armaly MF. Statistical attributes of the steroid hypertensive response in the clinically normal eye. The demonstration of three levels of response. Invest Ophthalmol 1965; 4: 187.
48. Schwartz JT, Reuling FH, Feinlieb M, Garrison RJ, Collie DJ. Twin study on ocular pressure following topically applied dexamethasone: II. Inheritance of variation in pressure response. Arch Ophthalmol 1973; 90: 281-286.
49. Palmberg PE, Mandell A, Wilensky JT, Podos SM, Becker B. The reproductivity of the intraocular pressure response to dexamethasone. Am J Ophthalmol 1975; 80: 844-856.
50. Lo WR, Rowlette LL, Caballero M, Yang F, Hernandez MR, Borras T. Tissue differential microarray analysis of dexamethasone induction reveals potential mechanisms of steroid induced glaucoma. Invest Ophthalmol Vis Sci 2003; 44: 473-485.
51. Polansky JR, Fauss DJ, Chen F, Chen H, Liltjen-Drecoll E, Johnson D et al. Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica 1997; 21: 126-139.
52. Nguyen TD, Chen P, Huang WD, Chen H, Johnson D, Polansky JR. Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells. J Biol Chem 1998; 273: 6341-6350.
53. Ortego J, Escribano J, Coca-Prados M. Cloning and characterization of subtracted cDNAs from human ciliary body library encoding TIGR, a protein involved in juvenile open angle glaucoma with homology to myocilin and olfactomedin. FEBS Lett 1997; 413: 349-353.
54. Alward WLM. The genetics of open-angle glaucoma: The story of GLC1A and myocilin. Eye 2000; 14: 429-436.
55. Alward WLM, Fingert JH, Coote MA, Johnson T, Lerner SF, Junqua D et al. Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A). N Engl J Med 1998; 338: 1022-1027.
56. Tamm ER. Myocilin and glaucoma: Facts and ideas. Prog Retina Eye Res 2002; 21: 395-428.
57. Zilling M, Wurm A, Grehn FJ, Russell F, Tamm ER. Overexpression and properties of wild-type and Tyr437His mutated myocilin in the eyes of transgenic mice. Invest Ophthalmol Vis Sci 2005; 46: 223-234.
58. Gould DB, Miceli-Libby L, Savincva OV, Torrado M, Tomarev SI, Smith RS et al. Genetically increasing Myoc expression supports a necessary pathological role of abnormal proteins in glaucoma. Mol Cell Biol 2004; 24: 9019-9025.
59. Fingert JH, Clark AF, Craig JE, Alward WLM, Snibson GR, McLaughin M et al. Evaluation of the myocilin (MYOC) glaucoma gene in monkey and human steroid-induced ocular hypertension. Invest Ophthalmol Vis Sci 2001; 42: 145-152.
60. Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol 2004; 138: 740-743.
61. Espildora J, Vicuna P, Diaz E. Cortisone-induced glaucoma: A report on 44 affected eyes. J Fr Ophthalmol 1981; 4: 503-508.
62. Goldberg I. Ocular inflammatory and steroid-induced glaucoma. In: Yanoff M, Duker JS (eds) Ophthalmology, 2nd edn. Mosby: St Louis, MO, 2004, pp 1512-1517.
63. Scherer WJ, Hauber FA. Effect of latanoprost on intraocular pressure in steroid induced glaucoma. J Glaucoma 2000; 9: 179-182.
64. Smith SL, Pruitt CA, Sine CS, Hudgins AC, Stewart WC. Latanoprost 0.005% and anterior segment uveitis. Acta Ophthalmol Scand 1999; 77: 668-672.
65. Warwar RE, Bullock JD, Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998; 105: 263-268.
66. Byles DB, Frith F, Salmon JF. Anterior uveitis as a side effect of topical brimonidine. Am J Ophthalmol 2000; 130: 287-291.
67. Galin MA, Hirschman H, Gould H, Hofmann I. Does laser trabeculoplasty prevent steroid glaucoma? Ophthalmic Surg Lasers 2000; 31(2): 107-110.
68. Skuta G, Morgan RK. Corticosteroid glaucoma. In: Shields MB (ed). Textbook of Glaucoma, 4th ed. Williams & Wilkins:BAltimore, MD/London, 1998, pp 1177-1188.
69. Thomas R, Jay JL. Raised intraocular pressure with topical steroids after trabeculectomy. Grafes Arch Clin Exp Ophthalmol 1988; 226: 337-340.
70. Herschler J. Intractable intraocular hypertension induced by repository triamcinolone acetonide. Am J Ophthalmol 1972; 74: 501-504.
71. Herschler J. Increased intraocular pressure induced by repository corticosteroid. Am J Ophthalmol 1976; 82: 90-93.
72. Ferry AP, Harris WP, Nelson MH. Histopathologic features of subconjunctivally injected corticosteroid. Am J Ophthalmol 1987; 103: 716-718.
73. Merayo-Lloves J, Power WJ, Rodriguez A, Pedroza-Serer M, Foster CS. Secondary glaucoma in patients with uveitis. Ophthalmologica 1999; 213: 300-304.
74. Toris CB, Pederson JE. Aqueous humor dynamics in experimental iridocyclitis. Invest Ophthalmol Vis Sci 1987; 28: 477-481.
75. Kok H, Barton K. Uveitic glaucoma. Ophthalmol Clin N Am 2002; 15: 375-387.
76. Phillips CI, Green K, Gore SM, Cullen PM, Campell M. Eye drops of RU 486-6, a peripheral steroid blocker, lower intraocular pressure in rabbits. Lancet 1984; 1: 767.
77. Green K, Cheeks L, Slagle T, Phillips CI. Interaction between progesterone and mifepristerone on intraocular pressure in rabbits. Curr Eye Res 1989; 8: 317.
78. Southren AL, Wandel T, Gordon GG, Weinstein BI. Treatment of primary open angle glaucoma with 3α,5β-tetrahydrocortisol: New therapeutic modality. J Ocul Pharmacol 1994; 10: 385-391.
79. Southren AL, L'Hommedieu D, Gordon GG, Weinstein BI. Intraocular hypotensive effect of a topically applied cortisol metabolite: 3α,5β-Terahydrocortisol. Invest Ophthalmol Vis Sci 1987; 28: 901.
80. Clark AF, Wilson K, Miggans ST, Lane D. Tetrahydrocortisol inhibits dexamethasone induced cytoskeletal reorganization in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci 1993; 34(Suppl): 1140.